Roche Holding AG (ROP) - Total Assets
Based on the latest financial reports, Roche Holding AG (ROP) holds total assets worth CHF100.70 Billion CHF (≈ $127.32 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Roche Holding AG to assess the company's total reinvestment commitment from operating cash flow.
Roche Holding AG - Total Assets Trend (1998–2025)
This chart illustrates how Roche Holding AG's total assets have evolved over time, based on quarterly financial data. Check earnings quality score of Roche Holding AG to evaluate the quality of earnings relative to operating cash generation.
Roche Holding AG - Asset Composition Analysis
Current Asset Composition (December 2025)
Roche Holding AG's total assets of CHF100.70 Billion consist of 38.5% current assets and 61.5% non-current assets.
| Asset Category | Amount (CHF) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 5.5% |
| Accounts Receivable | CHF11.90 Billion | 11.8% |
| Inventory | CHF7.48 Billion | 7.4% |
| Property, Plant & Equipment | CHF0.00 | 0.0% |
| Intangible Assets | CHF19.32 Billion | 19.2% |
| Goodwill | CHF7.49 Billion | 7.4% |
Asset Composition Trend (1998–2025)
This chart illustrates how Roche Holding AG's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ROP market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Roche Holding AG's current assets represent 38.5% of total assets in 2025, a decrease from 50.0% in 1998.
- Cash Position: Cash and equivalents constituted 5.5% of total assets in 2025, up from 3.6% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 0.0% in 1998.
- Asset Diversification: The largest asset category is intangible assets at 19.2% of total assets.
Roche Holding AG Competitors by Total Assets
Key competitors of Roche Holding AG based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
AstraZeneca PLC
MX:AZNN
|
Mexico | MX$114.07 Billion |
|
Novartis AG
MX:NVSN
|
Mexico | MX$118.53 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
AstraZeneca PLC
F:ZEGA
|
Germany | €114.46 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
Chongqing Lummy Pharmaceutical
SHE:300006
|
China | CN¥2.76 Billion |
|
Hangzhou Minsheng Healthcare Co Ltd
SHE:301507
|
China | CN¥2.09 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
Roche Holding AG - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.38 | 1.48 | 1.30 |
| Quick Ratio | 1.12 | 1.20 | 1.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CHF10.73 Billion | CHF13.01 Billion | CHF7.54 Billion |
Roche Holding AG - Advanced Valuation Insights
This section examines the relationship between Roche Holding AG's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.45 |
| Latest Market Cap to Assets Ratio | 2.49 |
| Asset Growth Rate (YoY) | -1.1% |
| Total Assets | CHF100.70 Billion |
| Market Capitalization | $250.86 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Roche Holding AG's assets at a significant premium (2.49x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Roche Holding AG's assets decreased by 1.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Roche Holding AG (1998–2025)
The table below shows the annual total assets of Roche Holding AG from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CHF100.70 Billion ≈ $127.32 Billion |
-1.08% |
| 2024-12-31 | CHF101.80 Billion ≈ $128.70 Billion |
+12.53% |
| 2023-12-31 | CHF90.47 Billion ≈ $114.38 Billion |
+2.63% |
| 2022-12-31 | CHF88.15 Billion ≈ $111.45 Billion |
-4.51% |
| 2021-12-31 | CHF92.32 Billion ≈ $116.71 Billion |
+7.17% |
| 2020-12-31 | CHF86.14 Billion ≈ $108.90 Billion |
+3.67% |
| 2019-12-31 | CHF83.09 Billion ≈ $105.05 Billion |
+5.83% |
| 2018-12-31 | CHF78.52 Billion ≈ $99.27 Billion |
+2.40% |
| 2017-12-31 | CHF76.68 Billion ≈ $96.94 Billion |
-0.19% |
| 2016-12-31 | CHF76.82 Billion ≈ $97.12 Billion |
+1.39% |
| 2015-12-31 | CHF75.76 Billion ≈ $95.78 Billion |
+0.30% |
| 2014-12-31 | CHF75.54 Billion ≈ $95.50 Billion |
+21.51% |
| 2013-12-31 | CHF62.17 Billion ≈ $78.60 Billion |
-4.07% |
| 2012-12-31 | CHF64.81 Billion ≈ $81.93 Billion |
+5.24% |
| 2011-12-31 | CHF61.58 Billion ≈ $77.85 Billion |
+0.91% |
| 2010-12-31 | CHF61.02 Billion ≈ $77.15 Billion |
-18.17% |
| 2009-12-31 | CHF74.56 Billion ≈ $94.27 Billion |
-2.00% |
| 2008-12-31 | CHF76.09 Billion ≈ $96.20 Billion |
-2.68% |
| 2007-12-31 | CHF78.18 Billion ≈ $98.84 Billion |
+5.06% |
| 2006-12-31 | CHF74.41 Billion ≈ $94.08 Billion |
+7.28% |
| 2005-12-31 | CHF69.36 Billion ≈ $87.70 Billion |
+19.44% |
| 2004-12-31 | CHF58.08 Billion ≈ $73.42 Billion |
-2.37% |
| 2003-12-31 | CHF59.49 Billion ≈ $75.21 Billion |
-7.05% |
| 2002-12-31 | CHF63.99 Billion ≈ $80.91 Billion |
-15.00% |
| 2001-12-31 | CHF75.29 Billion ≈ $95.18 Billion |
+8.27% |
| 2000-12-31 | CHF69.53 Billion ≈ $87.91 Billion |
-1.27% |
| 1999-12-31 | CHF70.43 Billion ≈ $89.04 Billion |
+26.04% |
| 1998-12-31 | CHF55.88 Billion ≈ $70.65 Billion |
-- |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more